Vivos Therapeutics Financial Results
Vivos Therapeutics reported Q3 2026 financial results, highlighting a 24% sequential revenue increase to $6.4 million and an 18% year-over-year improvement in operating loss. The company successfully regained compliance with Nasdaq's stockholders' equity requirement following debt-for-equity exchanges and the closing of its SOD Sciences transaction.
- Term
- Q3 2026
“During the third quarter of 2026, we took decisive steps to reduce costs and strengthen our balance sheet. Our operating loss improved 18% compared to the prior-year quarter, general and administrative and sales and marketing expenses together declined by $1.6 million, and we have now eliminated an estimated $5 million or more in annual operating costs, with further efficiencies underway.”
Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer
“We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.”
Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer